Literature DB >> 32701117

What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?

Yu Shyr1,2,3, Derek Shyr4.   

Abstract

Entities:  

Year:  2020        PMID: 32701117      PMCID: PMC7780730          DOI: 10.1001/jamaoncol.2020.1847

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Pathological complete response in neoadjuvant treatment of breast cancer.

Authors:  Patricia Cortazar; Charles E Geyer
Journal:  Ann Surg Oncol       Date:  2015-03-02       Impact factor: 5.344

Review 2.  Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Authors:  Christopher J Weir; Rosalind J Walley
Journal:  Stat Med       Date:  2006-01-30       Impact factor: 2.373

Review 3.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

Review 4.  The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Authors:  Vinay Prasad; Chul Kim; Mauricio Burotto; Andrae Vandross
Journal:  JAMA Intern Med       Date:  2015-08       Impact factor: 21.873

5.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

6.  Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

Authors:  Douglas Yee; Angela M DeMichele; Christina Yau; Claudine Isaacs; W Fraser Symmans; Kathy S Albain; Yunn-Yi Chen; Gregor Krings; Shi Wei; Shuko Harada; Brian Datnow; Oluwole Fadare; Molly Klein; Stefan Pambuccian; Beiyun Chen; Kathi Adamson; Sharon Sams; Paulette Mhawech-Fauceglia; Anthony Magliocco; Mike Feldman; Mara Rendi; Husain Sattar; Jay Zeck; Idris T Ocal; Ossama Tawfik; Lauren Grasso LeBeau; Sunati Sahoo; Tuyethoa Vinh; A Jo Chien; Andres Forero-Torres; Erica Stringer-Reasor; Anne M Wallace; Lajos Pusztai; Judy C Boughey; Erin D Ellis; Anthony D Elias; Janice Lu; Julie E Lang; Hyo S Han; Amy S Clark; Rita Nanda; Donald W Northfelt; Qamar J Khan; Rebecca K Viscusi; David M Euhus; Kirsten K Edmiston; Stephen Y Chui; Kathleen Kemmer; John W Park; Minetta C Liu; Olufunmilayo Olopade; Brian Leyland-Jones; Debasish Tripathy; Stacy L Moulder; Hope S Rugo; Richard Schwab; Shelly Lo; Teresa Helsten; Heather Beckwith; Patricia Haugen; Nola M Hylton; Laura J Van't Veer; Jane Perlmutter; Michelle E Melisko; Amy Wilson; Garry Peterson; Adam L Asare; Meredith B Buxton; Melissa Paoloni; Julia L Clennell; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Jeffrey B Matthews; Smita M Asare; Ashish Sanil; Scott M Berry; Laura J Esserman; Donald A Berry
Journal:  JAMA Oncol       Date:  2020-09-01       Impact factor: 31.777

  6 in total
  3 in total

Review 1.  Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.

Authors:  Jamie E Chaft; Yu Shyr; Boris Sepesi; Patrick M Forde
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

2.  Neoadjuvant Chemotherapy for Breast Cancer: The Ultimate "Spy".

Authors:  Carla Suzanne Fisher
Journal:  Ann Surg Oncol       Date:  2022-08-04       Impact factor: 4.339

3.  A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer.

Authors:  Bishal Gyawali; Elvira D'Andrea; Jessica M Franklin; Aaron S Kesselheim
Journal:  EClinicalMedicine       Date:  2021-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.